Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fielmann Group AGFRA:FIE1 +0.67%80 Debt-to-Equity is 0.54 as of Jun. 2026, which is 2% above its 10-year median of 0.53. GuruFocus rates FRA:FIE1 with a GF Score™ of 80/100 and a GF Value™ of €10.08. The stock has 2 warning signs investors should review. Among 696 Medical Devices & Instruments companies, Fielmann Group AG ranks worse than 71.12% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Fielmann Group AG's Debt-to-Equity or its related term are showing as below:
FRA:FIE1'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.53 Max: 0.96
Current: 0.54
During the past 13 years, the highest Debt-to-Equity Ratio of Fielmann Group AG was 0.96. The lowest was 0.00. And the median was 0.53.
FRA:FIE1's Debt-to-Equity is ranked worse than 71.12% of 696
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs FRA:FIE1: 0.54
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Fielmann Group AG Debt-to-Equity Related Terms
Fielmann Group AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Fielmann Group AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FIE1 vs ISRG, BDX, MDLN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Fielmann Group AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fielmann Group AG Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fielmann Group AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Fielmann Group AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fielmann Group AG (FRA:FIE1) has a Debt-to-Equity of 0.54 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fielmann Group AG and its competitors. This is near median its historical median of 0.53. According to the industry distribution chart, Fielmann Group AG ranks #495 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 71.1%.
Is Fielmann Group AG's Debt-to-Equity too high?
Fielmann Group AG's current Debt-to-Equity of 0.54 is near median its 10-year median of 0.53. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Fielmann Group AG's value of 0.54 is 125% above this industry median. Based on the distribution chart, Fielmann Group AG ranks #495 out of 696 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Fielmann Group AG has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Fielmann Group AG's Debt-to-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fielmann Group AG ranks #495 out of 696 companies for Debt-to-Equity. This places Fielmann Group AG in the lower half of its industry. The industry median Debt-to-Equity is 0.24. Fielmann Group AG's value of 0.54 is 125% above this benchmark. While the company's 10-year median is 0.53 vs. the industry median of 0.24, Fielmann Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fielmann Group AG's current Debt-to-Equity of 0.54 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fielmann Group AG and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fielmann Group AG's current Debt-to-Equity is 0.54, which is near median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fielmann Group AG stock overvalued right now?
Fielmann Group AG (FRA:FIE1) has a current Debt-to-Equity of 0.54. The stock's GF Value™ is €10.08, compared to a current price of €7.55 — trading 25.1% below its estimated fair value. The current Debt-to-Equity is 0.54, which is near median its 10-year median of 0.53 and 125% above the Medical Devices & Instruments industry median of 0.24. Fielmann Group AG's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Fielmann Group AG (FRA:FIE1), the current Debt-to-Equity is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fielmann Group AG (FRA:FIE1) Overvalued in 2026?
Based on GuruFocus' analysis, Fielmann Group AG stock appears to be undervalued.
The current stock price of €7.55 is trading 25.1% below its estimated GF Value™ of €10.08.
Key valuation signals for FRA:FIE1:
Debt-to-Equity: 0.54 (near median its 10-year median of 0.53)
GF Value™: €10.08 vs. price of €7.55 (25.1% below fair value)
Industry Position: 125% above the Medical Devices & Instruments median (#495 of 696)
No single metric tells the full story. See the FRA:FIE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fielmann Group AG is involved in the purchase and sale of goods, in physical stores as well as wholesale and online, particularly in the optometric and hearing acoustics sectors, and especially sales of all kinds of vision aids - particularly glasses, eyeewear frames and lenses, sunglasses, contact lenses, accessories, hearing systems, as well as personal protective equipment. Fielmann is involved in all levels of the optical industry value-added chain: designing, manufacturing, product offering, and optician services. The group was divided into six segments: Germany, Switzerland, Austria, Spain, North America, and Other. The majority of its revenue is generated from Germany.
80GF Score
Get the complete analysis for FRA:FIE1
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FIE1 has been successfully added to your 
